NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Host Factors in Invasive and Recurrent Staphylococcus Aureus Infection

Terminated

Conditions: Staphylococcal Aureus Infection
Invasive Staphylococcal Infection
Recurrent Staphylococcal Infection

First Posted Date: 2009-06-02

Last Posted Date: 2019-12-17

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 22

Registration Number: NCT00911430

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Early Immune Responses to Vaccination - A Substudy to HVTN 205

Completed

Conditions: HIV Infections

Interventions: Biological: JS7 DNA vaccine
Biological: MVA/HIV62 vaccine

First Posted Date: 2009-05-25

Last Posted Date: 2021-10-15

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 47

Registration Number: NCT00908323

Locations: 🇺🇸
Seattle Vaccine and Prevention CRS, Seattle, Washington, United States
🇺🇸
Bridge HIV CRS, San Francisco, California, United States
🇺🇸
Alabama Vaccine CRS, Birmingham, Alabama, United States

Influenza Vaccine in Pregnant Women

Phase 2

Completed

Conditions: Influenza

Interventions: Biological: Fluarix®
Biological: Fluzone®

First Posted Date: 2009-05-20

Last Posted Date: 2012-06-13

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 102

Registration Number: NCT00905125

Locations: 🇺🇸
Emory University School of Medicine - Gynecology and Obstetrics, Atlanta, Georgia, United States
🇺🇸
Saint Louis University, St. Louis, Missouri, United States
🇺🇸
Baylor College of Medicine - Molecular Virology and Microbiology, Houston, Texas, United States

and more 6 locations

Nontypeable H. Influenzae in Healthy Adults

Phase 1

Completed

Conditions: Haemophilus Influenzae (NTHI)

Interventions: Biological: NTHi Strain 2019

First Posted Date: 2009-05-20

Last Posted Date: 2013-04-11

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 15

Registration Number: NCT00905385

Locations: 🇺🇸
University of Iowa - Infectious Disease Clinic, Iowa City, Iowa, United States

Establishing Fibroblast-Derived Cell Lines From Skin Biopsies of Patients With Immunodeficiency or Immunodysregulation Disorders

Conditions: Virus Susceptibility
Primary Immunodeficiency
DOCK8

First Posted Date: 2009-05-08

Last Posted Date: 2025-06-10

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 200

Registration Number: NCT00895271

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Viral Triggers in Pediatric Lung Transplantation

Completed

Conditions: Lung Transplant
Obliterative Bronchiolitis
Bronchiolitis Obliterans

First Posted Date: 2009-05-01

Last Posted Date: 2020-07-02

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 61

Registration Number: NCT00891865

Locations: 🇺🇸
Stanford University, Palo Alto, California, United States
🇺🇸
Nationwide Children's Hospital, Columbus, Ohio, United States
🇺🇸
Texas Children's Hospital, Houston, Texas, United States

and more 3 locations

A Randomized, Double-Blind, Placebo-Controlled Study of Omalizumab for Idiopathic Anaphylaxis

Phase 2

Completed

Conditions: Angioedema
Hypotension
Bronchospasm
Anaphylaxis

Interventions: Drug: Epinephrine
Drug: Placebos
Drug: Omalizumab (Xolair)

First Posted Date: 2009-04-29

Last Posted Date: 2019-07-01

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 16

Registration Number: NCT00890162

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Phase I Study of the Safety and Immunogenicity of BSAM-2/Alhydrogel +CPG 7909, an Asexual Blood Stage Vaccine for Plasmodium Falciparum Malaria in Adults in the US and Mali

Phase 1

Completed

Conditions: Malaria

First Posted Date: 2009-04-29

Last Posted Date: 2019-12-17

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 154

Registration Number: NCT00889616

Locations: 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇲🇱
Malaria Research and Training Center, Bamako, Mali

Pathogenesis of Physical Induced Urticarial Syndromes

Completed

Conditions: Physical Urticaria
Hypersensitivity, Immediate
Autoinflammatory Syndromes
Familial Cold Autoinflammatory Syndrome

First Posted Date: 2009-04-24

Last Posted Date: 2025-06-10

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 173

Registration Number: NCT00887939

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

High-Dose Fluconazole for the Treatment of Cryptococcal Meningitis in HIV-Infected Individuals

Phase 1

Completed

Conditions: Cryptococcal Meningitis
HIV Infections

Interventions: Drug: Fluconazole
Drug: Amphotericin B

First Posted Date: 2009-04-22

Last Posted Date: 2021-11-04

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 168

Registration Number: NCT00885703

Locations: 🇺🇬
Joint Clinical Research Centre (JCRC)/Kampala Clinical Research Site, Kampala, Uganda
🇿🇦
Durban International Clinical Research Site CRS, Durban, KwaZulu-Natal, South Africa
🇺🇸
University of Southern California CRS, Los Angeles, California, United States

and more 7 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy